Response to Lim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".

Abstract

Stem Cells and DevelopmentVol. 29, No. 14 Letters To The EditorResponse to Lim et al. re: “Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19”Vikram Sengupta, Sascha Sengupta, Angel Lazo Jr., Kevin C. Hicok, and Timothy MoseleyVikram SenguptaAddress correspondence to: Dr. Vikram Sengupta, Department of Internal Medicine, NYU Grossman School of Medicine, 550 1st Avenue, New York, NY 10016, USA E-mail Address: vikram.sengupta@nyulangone.orgDepartment of Internal Medicine, NYU Grossman School of Medicine, New York, New York, USA.Thrivewell Infusion, LLC, Brooklyn, New York, USA.Search for more papers by this author, Sascha SenguptaThrivewell Infusion, LLC, Brooklyn, New York, USA.Department of Anesthesiology, Mount Sinai Hospital-Brooklyn, Brooklyn, New York, USA.Search for more papers by this author, Angel Lazo Jr.Department of Internal Medicine, Englewood Hospital, Englewood, New Jersey, USA.Search for more papers by this author, Kevin C. HicokDepartment of Research and Development, Direct Biologics LLC, Austin, Texas, USA.Search for more papers by this author, and Timothy MoseleyDepartment of Research and Development, Direct Biologics LLC, Austin, Texas, USA.Search for more papers by this authorPublished Online:9 Jul 2020https://doi.org/10.1089/scd.2020.0095AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byMeet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS‐CoV‐230 November 2022 | Journal of Extracellular Vesicles, Vol. 11, No. 12Immunomodulatory extracellular vesicles: an alternative to cell therapy for COVID-1924 May 2021 | Expert Opinion on Biological Therapy, Vol. 21, No. 12Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects21 August 2021 | Stem Cell Research & Therapy, Vol. 12, No. 1Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials12 July 2021 | Expert Review of Anti-infective Therapy, Vol. 19, No. 10The clinical role of host and bacterial-derived extracellular vesicles in pneumoniaAdvanced Drug Delivery Reviews, Vol. 176Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases27 March 2021 | Biotechnology and Bioengineering, Vol. 22Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia11 July 2020 | Critical Care, Vol. 24, No. 1COVID‐19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?14 November 2020 | Journal of Extracellular Vesicles, Vol. 10, No. 1Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment3 July 2020 | Frontiers in Immunology, Vol. 11 Volume 29Issue 14Jul 2020 InformationCopyright 2020, Mary Ann Liebert, Inc., publishersTo cite this article:Vikram Sengupta, Sascha Sengupta, Angel Lazo Jr., Kevin C. Hicok, and Timothy Moseley.Response to Lim et al. re: “Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19”.Stem Cells and Development.Jul 2020.879-881.http://doi.org/10.1089/scd.2020.0095Published in Volume: 29 Issue 14: July 9, 2020Online Ahead of Print:June 10, 2020PDF download